Posts for Ticker ‘AOB’

Top Day Trader Alerts (AOB, DPTR, ETFC, C, FNM, FRE, AIG)

These are this Tuesday morning’s top day trader alert stocks and actively trade stocks.  We have more detailed price and volume analysis and data on each stock with links provided through at VSInvestor.com:

American Oriental Bioengineering Inc. (NYSE: AOB) is down after Asensio.com panned some issues inside the company.  Delta Petroleum Corp. (NASDAQ: DPTR) is trading fairly well considering its 45% drop yesterday.  We are seeing much trading interest in the return of the junk-financial stocks.  E*TRADE Financial Corporation (NASDAQ: ETFC) is up another 4% pre-market and taking out near-term resistance.  Citigroup, Inc. (NYSE: C) is up after Singapore lightened its share ownership stake.

Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE) are even hitting September highs.  If you want proof that the financial risk trade is coming back on, even American International Group, Inc. (NYSE: AIG) is up over 10% and over $50.00 this morning and challenging those late August highs.

You can join our open email distribution list which goes out several times per week for top day trader alerts, analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG

Posted on: September 22, 2009 – 9:02 am in After-Hours Activity, Financial Stocks, Pre-Market Activity, Trading Alert, , , , , , ,

Biotech Business Daily (RIGL, BIIB, ARRY, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth coverage and analysis today at the website BioHealthInvestor.com:

Rigel Pharmaceuticals Inc.’s (NASDAQ: RIGL) Phase IIb trial results Thursday morning of its rheumatoid arthritis candidate R788, is boosting its stock on speculation it may help the company attract a clinical partner.

Biogen Idec Inc. (NASDAQ: BIIB) is enjoying a second day of gains after its new PEGylated interferon beta-1a (BIIB017) for relapsing multiple sclerosis (RMS) received an FDA Fast Track designation.  This might be a game-changing event for the company with some risks as well.

Array BioPharma Inc. (Nasdaq: ARRY) now says it will discontinue development of ARRY-797 in chronic inflammatory diseases. Attention may now turn to Array’s ARRY-162, another anti-inflammatory that showed much more promising efficacy.

Also, see our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 9, 2009 – 11:09 am in Biotech, Drug companies, FDA, Medical, , , , , , , ,

BioHealth Business Daily (CI, AET, MYL, JAZZ, PTIE, GSK, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that are covered in-depth today at BioHealthInvestor.com:

Cigna corp. (NYSE: CI), Aetna Inc. (NYSE: AET), and other managed care companies are rising despite making health care reform concessions, as shareholders see they have a seat at the bargaining table.

Mylan Inc. (NASDAQ: MYL) has received FDA approval for a generic version of an AstraZeneca (AZN) prostate cancer drug — a rather unusual new generic.

Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) shares are up more than 25 percent after the company took steps to ease a cash crunch that had curtailed drug development.

King Pharmaceuticals (KG) and Pain Therapeutics (PTIE) said  they expect to resubmit a new drug application in mid-2010, slightly later than anticipated.

GlaxoSmithKline (NYSE: GSK) announced a positive study on its Cervarix vaccine, although it’s unclear if the company can play catch-up to Merck & Co.’s (NYSE: MRK) Gardasil.

See our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 7, 2009 – 11:03 am in Biotech, Drug companies, FDA, Medical, Trading Alert, , , , , , , , , , ,

The Five Growth Biotech Names To Watch Right Now

biotechAlnylam (Nasdaq: ALNY) leads a short list of some of the fastest-growing biotech stocks
where analyst estimate revisions continue to rise.

BioHealth Investor began by analyzing 171 stocks in the biotech sector based on revenue growth over the trailing four quarters, identifying 30 stocks in the sector with better
than 50 percent revenue growth over the past 12 months.

We then screened those 30 stocks to look for those very few names that have seen both strong growth in at least the past two years and positive analyst estimate revisions in recent months, in an effort to find stocks with strong trends that still have potentially improving operations going forward.

The work resulted in growth biotech stocks to watch: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM). Read More »

Posted on: July 6, 2009 – 4:27 am in Biotech, , , , ,

Biotech News Day (February 4, 2008) (AMAG, AOB, AMGN, CELG, MNTA, OMRI, SVA, STEM)

Below are some of the top issues affecting biotech shares today:

  • AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company developing iron compounds to treat anemia, saw shares rise 4% to $56.00 after brokerage firm Robert W. Baird initiated coverage with an OUTPERFORM rating.
  • American Oriental Bioengineering Inc. (NYSE:AOB) shares are down almost 7% at mid-day with relative high volume trading to $9.50 on no real news.
  • Amgen Inc. (NASDAQ:AMGN) stock shows no reaction to deal with Japanese drug giant Takeda Pharmaceutical. Takeda is to purchase Amgen’s Japanese unit for up to $902 million plus royalties on sales in exchange for access to 13 of Amgen’s new drugs. Amgen hopes this will curb costs and provide cash as their high-selling anemia drug sales slow due to safety issues. 
  • Celgene Corporation (NASDAQ:CELG) shares are down $1.76 to $57.94 at mid-day. Although earnings reported last Thursday met Wall Street expectations, the outlook for the success of its multiple myeloma cancer treatment, Revlimid, is mixed. Today, the company released Phase II data and news for its psoriasis drug CC-10004. The recent study showed positive results and the company announced plans to increase dosages. 
  • Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) shares continued to take a beating after they announced their earnings release date this morning. They had a rough quarter after the FDA rejected their genetic blood-thinner in November, losing about 60% of its share price. Shares are down $0.37 to $7.54 at mid-day. 
  • Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI) shares are slightly recovering today after a sharp plummet over the last 2 weeks following the FDA approval for competitor ZymoGenetics’ (ZGEN) Recothrom, that will compete with Omrix’s Evithrom in the thrombin drug market. Omrix announced last Friday that their CFO is resigning. Shares are up 4% to $21.27 on relatively heavy trading volume at mid-day. A month ago, shares were trading at over $30. 
  • Sinovac Biotech Ltd. (AMEX:SVA), the Chinese vaccine provider, has shares up over 5% to $4.11 at mid-day after Sinovec announced the private placement of 2,500,000 common shares for $9.75 million to Sansar Capital Management. 
  • StemCells Inc. (NASDAQ:STEM) stock continued to rise after news last Thursday that it plans to collaborate with Casey Eye Institute to study their leading product candidate, HuCNS-SC, a probable treatment for retinal degeneration which is a leading cause of blindness. Shares are up over 15% at mid-day to $1.77.

Rachel Lopez
February 4, 2008

Posted on: February 4, 2008 – 2:41 pm in Biotech, , , , , , , ,

Pre-Market Analyst Calls (July 13, 2007)

AOB started as Outperform at CIBC.
AUY started asOutperform at Credit Suisse.
BGFV cut to Sector Perform at CIBC.
BJ raised to Equal Weight at Lehman.
BLK started as Outperform at Wachovia.
CCL raised to Overweight at JPMorgan.
CHE cut to Hold at Deutsche Bank.
CIT cut to Sector PErform at CIBC.
CREE started as Hold at Deutsche Bank.
DWA started as Buy at Stifel Nicolaus.
EMC cut to Mkt Perform at Morgan Keegan.
FRO cut to Reduce at UBS.
HAL raised to Outperform at Credit Suisse.
HDB started as Buy at Jefferies.
IBN started as Buy at Jefferies.
NATI raised to Overweight at Thomas Weisel.
NDN raised to Buy at Deutsche Bank.
PPDI cut to Hold at Jefferies.
RCL raised to Overweight at JPMorgan.
RNOW started as Hold at Cantor Fitzgerald.
RSH cut to Sell at B of A.
SEB raised to Buy at Jefferies.
SWK started as Neutral at B of A.
SWY raised to Equal Weight at Lehman.
VRSN raised to Buy at Jefferies.
VSCN cut to Mkt Perform at FBR.
WON cut to Sell at Citigroup.
ZBRA raised to Overweight at Thomas Weisel.

Jon C. Ogg
July 13, 2007

Posted on: July 13, 2007 – 6:43 am in Analyst Calls, , , , , , , , , , , , , , , , , , , , , , , ,

Pre-Market Stock News (June 13, 2007)

(AOB) American Oriental enters into a letter-of-intent to acquire an established plant based pharmaceutical company named Changchun Xinan Pharmaceutical Group for up to $30 million.
(CEN) Ceridian largest shareholder says the private equity buyout is underpriced.
(EBAY) eBay is still in court over this MercExchange LLC patent over its “Buy It Now” patent.
(F) Ford confirmed that it is reviewing sales of Jaguar and Rover; Goldman Sachs and others hired.
(GWR) Genesee & Wyoming reported a total carload decrease of 0.3%.
(GYI) Getty Images announced it has filed its 10-K for 2006.
(HS) Healthspring lowered guidance.
(LWSN) Lawson Software raised guidance to $0.05 to $0.07 EPS vs $0.04e.
(MAGS) Magal Security announced a new strategic partnership in Brazil for services providers.
(PAY) VeriFone Holdings announced it has been selected as the sole provider of electronic payment systems by the China Postal Savings Bank.
(POR) Portland General Electric announced the pricing of a 21 million share secondary at $26.00; seller is Enron Disputed Claims Reserve.
(SAPE) Sapient $0.07 EPS vs $0.01+e.
(SHLM) A. Schulman lowered guidance.
(SNY) Sanofi-Aventis diet drug all in one pill is being reviewed; already marketed as Acomplia in other countries.
(SSYS) Stratasys will replace LSS on S&P Small Cap 600 Index on June 14.
(TYC) Tyco will take a $500 Million pre-tax and $370 million after tax impairment charge for the sale of its Power Systems business.
(VLCM) Volcom will replace PXR on the S&P Small Cap 600 Index on June 15.

Jon C. Ogg
June 13, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 13, 2007 – 6:51 am in Pre-Market Activity, , , , , , , , , , , , , , , , ,